NBY vs. CWBR, RNAZ, ONCO, AGRX, SNOA, SXTP, ARAV, DRMA, CYTO, and SLRX
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include CohBar (CWBR), TransCode Therapeutics (RNAZ), Onconetix (ONCO), Agile Therapeutics (AGRX), Sonoma Pharmaceuticals (SNOA), 60 Degrees Pharmaceuticals (SXTP), Aravive (ARAV), Dermata Therapeutics (DRMA), Altamira Therapeutics (CYTO), and Salarius Pharmaceuticals (SLRX). These companies are all part of the "pharmaceutical preparations" industry.
CohBar (NASDAQ:CWBR) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.
In the previous week, NovaBay Pharmaceuticals' average media sentiment score of 0.00 equaled CohBar'saverage media sentiment score.
2.5% of CohBar shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 6.5% of CohBar shares are held by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
CohBar has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.
CohBar received 18 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 72.00% of users gave CohBar an outperform vote while only 0.00% of users gave NovaBay Pharmaceuticals an outperform vote.
NovaBay Pharmaceuticals has higher revenue and earnings than CohBar. CohBar is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CohBar has a net margin of 0.00% compared to CohBar's net margin of -65.46%. NovaBay Pharmaceuticals' return on equity of 0.00% beat CohBar's return on equity.
Summary
CohBar and NovaBay Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
